Pseudopteroxazole and Related Antitubercular Agents

拟蝶恶唑及相关抗结核药

基本信息

  • 批准号:
    7151457
  • 负责人:
  • 金额:
    $ 23.88万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-12-01 至 2008-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The goals of this work are to develop syntheses of antitubercular agents based on natural product leads. This will involve the total synthesis of the natural products pseudopteroxazole, seco-pseudopteroxazole, erogorgiaene, ileabethin, elisapterosin B and elisabethin A. Testing of targets and intermediates will be performed by the Tuberculosis Antimicrobial Acquisition and Coordinating Facility (TAACF). A unifying methodology will be developed in pursuing these goals. This involves the synthesis of enantiomerically pure benzothiazines through the intramolecular, stereoselective addition of sulfoximine carbanions to unsaturated esters. The development of this methodology will be coupled with aspects of other new chemistry to achieve the synthetic goals. Of particular importance will be the development of a stereoselective, intramolecular radical ring closure reaction as a means of establishing a six-membered ring. Two approaches to this general type of process will be explored. Benzothiazine chemistry will be further developed, particularly in the context of the synthesis of elisabethin A, during which the study of benzothiazine carbanions as nucleophiles in Michael addition reactions will be undertaken. The compounds to be prepared in this study will contribute to the goal of developing chemotherapeutics for tuberculosis. Since the targets are related to pseudopterosins, compounds with potent analgesic and antiinflammatory properties, the work will have an impact in this area as well. More generally, the methodology to be developed should have extremely broad impact, as it can be applied to the generation of stereogenic centers in a large number of compounds of biological and medicinal interest.
描述(由申请人提供):这项工作的目标是开发基于天然产物先导物的抗结核药物的合成。这将涉及天然产物假卟啉恶唑、次假卟啉恶唑、依绿霉素、依绿白素、elisapterosin B和elisisabethin a的全合成。靶点和中间体的检测将由结核病抗菌药物获取和协调机构(TAACF)进行。

项目成果

期刊论文数量(12)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Oxidation of 4-methoxyanilines to 1,4-benzoquinones using ceric ammonium nitrate (CAN).
  • DOI:
    10.1016/j.tetlet.2010.11.070
  • 发表时间:
    2011-01-26
  • 期刊:
  • 影响因子:
    1.8
  • 作者:
    Chen, Yugang;Ying, Weijiang;Harmata, Michael
  • 通讯作者:
    Harmata, Michael
Benzothiazines in organic synthesis. Stereoselectivity in the intermolecular Michael addition reactions of benzothiazines.
有机合成中的苯并噻嗪。
  • DOI:
    10.1021/ol701863y
  • 发表时间:
    2007
  • 期刊:
  • 影响因子:
    5.2
  • 作者:
    Harmata,Michael;Chen,Yugang;Barnes,CharlesL
  • 通讯作者:
    Barnes,CharlesL
Benzothiazines in synthesis. Further studies of the intramolecular, stereoselective addition of sulfonimidoyl carbanions to alpha,beta-unsaturated functional groups.
苯并噻嗪的合成。
  • DOI:
    10.1021/jo900151d
  • 发表时间:
    2009
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Harmata,Michael;Rayanil,Kanok-on;Espejo,VinsonR;Barnes,CharlesL
  • 通讯作者:
    Barnes,CharlesL
Preparation of S-2-halophenyl-2,1-benzothiazines.
S-2-卤代苯基-2,1-苯并噻嗪的制备。
  • DOI:
    10.1016/j.tet.2021.131991
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    2.1
  • 作者:
    Garimalla,Aswin;Harmata,Michael
  • 通讯作者:
    Harmata,Michael
Benzothiazines in synthesis. A formal total synthesis of pseudopteroxazole.
  • DOI:
    10.1021/jo9009112
  • 发表时间:
    2009-08-07
  • 期刊:
  • 影响因子:
    3.6
  • 作者:
    Harmata, Michael;Cai, Zhengxin;Chen, Yugang
  • 通讯作者:
    Chen, Yugang
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MICHAEL HARMATA其他文献

MICHAEL HARMATA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MICHAEL HARMATA', 18)}}的其他基金

Pseudopteroxazole and Related Antitubercular Agents
拟蝶恶唑及相关抗结核药
  • 批准号:
    6863274
  • 财政年份:
    2004
  • 资助金额:
    $ 23.88万
  • 项目类别:
Pseudopteroxazole and Related Antitubercular Agents
拟蝶恶唑及相关抗结核药
  • 批准号:
    6986743
  • 财政年份:
    2004
  • 资助金额:
    $ 23.88万
  • 项目类别:
BENZANNULATION APPROACH TO BIARYL ETHERS
二芳基醚的苯环化方法
  • 批准号:
    6386476
  • 财政年份:
    1999
  • 资助金额:
    $ 23.88万
  • 项目类别:
ARENE-FURAN PHOTOCYCLOADDITION REACTION
芳烃-呋喃光环加成反应
  • 批准号:
    3040463
  • 财政年份:
    1986
  • 资助金额:
    $ 23.88万
  • 项目类别:
ARENE-FURAN PHOTOCYCLOADDITION REACTION
芳烃-呋喃光环加成反应
  • 批准号:
    3040462
  • 财政年份:
    1985
  • 资助金额:
    $ 23.88万
  • 项目类别:

相似海外基金

Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
  • 批准号:
    10727507
  • 财政年份:
    2023
  • 资助金额:
    $ 23.88万
  • 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
  • 批准号:
    9194162
  • 财政年份:
    2016
  • 资助金额:
    $ 23.88万
  • 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
  • 批准号:
    496858-2016
  • 财政年份:
    2016
  • 资助金额:
    $ 23.88万
  • 项目类别:
    University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
  • 批准号:
    9201955
  • 财政年份:
    2015
  • 资助金额:
    $ 23.88万
  • 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
  • 批准号:
    8251289
  • 财政年份:
    2014
  • 资助金额:
    $ 23.88万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8302750
  • 财政年份:
    2012
  • 资助金额:
    $ 23.88万
  • 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
  • 批准号:
    267940
  • 财政年份:
    2012
  • 资助金额:
    $ 23.88万
  • 项目类别:
    Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8403458
  • 财政年份:
    2012
  • 资助金额:
    $ 23.88万
  • 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8549297
  • 财政年份:
    2012
  • 资助金额:
    $ 23.88万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8472443
  • 财政年份:
    2012
  • 资助金额:
    $ 23.88万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了